|
|
 |
|
Viewing report
|
|
|
Thought Leader Insight & Analysis Report - Osteoporosis Q2 2011
Medpredict, June 2011, Pages: 147
Osteoporosis Thought Leader Panel #52 challenges the osteoporosis treatment model that has been used worldwide for the last 25 years (the bisphosphonate era). After getting our Panelists to agree that the current prevention strategy has been an economic failure, we ask them how newer anabolic and antiresorptive therapies should be used in the future. What should be the role for an anti-sclerostin MAb? A cathepsin-K inhibitor? An alternative PTH dose form? An oral calcitonin? Strontium?
In addition to commenting on these and other mechanisms of action, the Panel also weighs in on atypical fractures, induction vs. maintenance, pricing and reimbursement, calcium risks vs. benefits and antiresorptive holidays.
|
|
|
|
